---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282854389.md"
description: "Immutep shares are trading higher after the FDA granted the company Orphan Drug Designation for for eftilagimod alfa for the treatment of Soft Tissue Sarcoma"
datetime: "2026-04-15T12:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282854389.md)
  - [en](https://longbridge.com/en/news/282854389.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282854389.md)
generator: "portal-rs"
---

# 

Immutep shares are trading higher after the FDA granted the company Orphan Drug Designation for for eftilagimod alfa for the treatment of Soft Tissue Sarcoma

### Related Stocks

- [IMMP.US](https://longbridge.com/en/quote/IMMP.US.md)
- [IMM.AU](https://longbridge.com/en/quote/IMM.AU.md)

## Related News & Research

- [IMM: Discontinuation of TACTI-004 caused impairment, but strong cash and positive clinical data support future prospects](https://longbridge.com/en/news/297439554.md)
- [IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity](https://longbridge.com/en/news/296543630.md)
- [UK£2.67: That's What Analysts Think Alfa Financial Software Holdings PLC (LON:ALFA) Is Worth After Its Latest Results](https://longbridge.com/en/news/298127570.md)
- [REG - Alfa Financial Soft - Director/PDMR Shareholding](https://longbridge.com/en/news/297925622.md)
- [Alfa Financial Software (LON:ALFA) Releases Quarterly Earnings Results](https://longbridge.com/en/news/298036168.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**